{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:18:48Z","timestamp":1790291928161,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11916-022-01077-z","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:03:03Z","timestamp":1662375783000},"page":"783-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Ann M.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie E.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-7172","authenticated-orcid":false,"given":"Chia-Chun","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"4","key":"1077_CR1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099\u2013142.","journal-title":"Physiol Rev"},{"issue":"1","key":"1077_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48\u201356.","journal-title":"Ann Neurol"},{"key":"1077_CR3","doi-asserted-by":"crossref","unstructured":"Durham PL, Cady R, and Cady R.\u00a0Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache, 2004. 44(1): p. 35\u201342; discussion 42\u20133.","DOI":"10.1111\/j.1526-4610.2004.04007.x"},{"issue":"9","key":"1077_CR4","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1523\/JNEUROSCI.19-09-03423.1999","volume":"19","author":"PL Durham","year":"1999","unstructured":"Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19(9):3423\u20139.","journal-title":"J Neurosci"},{"issue":"8","key":"1077_CR5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/j.1526-4610.2006.00538.x","volume":"46","author":"PL Durham","year":"2006","unstructured":"Durham PL, Niemann C, Cady R. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache. 2006;46(8):1291\u20135.","journal-title":"Headache"},{"issue":"1","key":"1077_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54\u201361.","journal-title":"Cephalalgia"},{"issue":"10","key":"1077_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179\u201386.","journal-title":"Cephalalgia"},{"issue":"22","key":"1077_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"1077_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026\u201337.","journal-title":"Cephalalgia"},{"issue":"6","key":"1077_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"10161","key":"1077_CR11","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"},{"issue":"6","key":"1077_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61(6):927\u201335.","journal-title":"Headache"},{"key":"1077_CR13","doi-asserted-by":"crossref","unstructured":"Reuter U, et al.\u00a0Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia, 2021: p. 3331024211053571.","DOI":"10.2139\/ssrn.3791424"},{"key":"1077_CR14","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, et al.\u00a0Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology, 2021.","DOI":"10.1212\/WNL.0000000000012029"},{"issue":"6","key":"1077_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40(6):543\u201353.","journal-title":"Cephalalgia"},{"issue":"4","key":"1077_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021;61(4):653\u201361.","journal-title":"Headache"},{"issue":"5","key":"1077_CR17","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"13","key":"1077_CR18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, et al. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40(13):1511\u201322.","journal-title":"Cephalalgia"},{"issue":"12","key":"1077_CR19","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"S de Vries Lentsch","year":"2021","unstructured":"de Vries Lentsch S, et al. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. Eur J Neurol. 2021;28(12):4194\u2013203.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1077_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61(9):1351\u201363.","journal-title":"Headache"},{"issue":"9","key":"1077_CR21","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014\u201325.","journal-title":"Headache"},{"issue":"Suppl 1","key":"1077_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, et al. Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci. 2019;40(Suppl 1):177\u20139.","journal-title":"Neurol Sci"},{"issue":"1","key":"1077_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"1","key":"1077_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.","journal-title":"J Headache Pain"},{"issue":"1","key":"1077_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84.","journal-title":"J Headache Pain"},{"issue":"1","key":"1077_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69.","journal-title":"J Headache Pain"},{"key":"1077_CR27","doi-asserted-by":"crossref","unstructured":"Raffaelli B, et al.\u00a0Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol.\u00a02020:11.","DOI":"10.3389\/fneur.2020.00417"},{"issue":"3","key":"1077_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, et al. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021;144(3):325\u201333.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1077_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","volume":"22","author":"A Straube","year":"2021","unstructured":"Straube A, et al. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22(1):133.","journal-title":"J Headache Pain"},{"issue":"10","key":"1077_CR30","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, et al. Erenumab in chronic migraine: an Australian experience. Headache. 2020;60(10):2555\u201362.","journal-title":"Headache"},{"key":"1077_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, et al. Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol. 2021;12: 805334.","journal-title":"Front Neurol"},{"issue":"1","key":"1077_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belvis","year":"2021","unstructured":"Belvis R, et al. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain. 2021;22(1):74.","journal-title":"J Headache Pain"},{"key":"1077_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.774341","volume":"12","author":"R Ornello","year":"2021","unstructured":"Ornello R, et al. Gender differences in 3-month outcomes of erenumab treatment-study on efficacy and safety of treatment with erenumab in men. Front Neurol. 2021;12: 774341.","journal-title":"Front Neurol"},{"key":"1077_CR34","unstructured":"A study to evaluate the efficacy and safety of fremanezumab for preventative treatment of migraine in patients with major depressive disorder. [Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04041284]."},{"issue":"9","key":"1077_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1077_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354.","journal-title":"Cephalalgia"},{"issue":"24","key":"1077_CR37","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"10","key":"1077_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814\u201325.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1077_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35.","journal-title":"J Headache Pain"},{"issue":"1","key":"1077_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"A.H.","year":"2019","unstructured":"Society, A.H. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"key":"1077_CR41","doi-asserted-by":"crossref","unstructured":"Sacco S, et al.\u00a0European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.\u00a0J Headache Pain, 2019. 20.","DOI":"10.1186\/s10194-018-0955-y"},{"key":"1077_CR42","unstructured":"Kwon S, Gil YE, Lee MJ. Efficacy of galcanezumab for the treatment of migraine in Korea: the first real-world data from an Asian country. in International Headache Society. 2021."},{"issue":"19","key":"1077_CR43","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999\u20132008.","journal-title":"JAMA"},{"issue":"22","key":"1077_CR44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"10203","key":"1077_CR45","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030\u201340.","journal-title":"Lancet"},{"issue":"1","key":"1077_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. 2021;22(1):68.","journal-title":"J Headache Pain"},{"issue":"18","key":"1077_CR47","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95(18):e2487\u201399.","journal-title":"Neurology"},{"issue":"1","key":"1077_CR48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156.","journal-title":"J Headache Pain"},{"issue":"3","key":"1077_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354.","journal-title":"Cephalalgia"},{"issue":"13","key":"1077_CR50","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365\u201377.","journal-title":"Neurology"},{"issue":"1","key":"1077_CR51","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21(1):126.","journal-title":"BMC Neurol"},{"issue":"7","key":"1077_CR52","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, et al. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60(7):1259\u201372.","journal-title":"Headache"},{"issue":"6","key":"1077_CR53","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60(6):1056\u201365.","journal-title":"Headache"},{"issue":"2","key":"1077_CR54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"key":"1077_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2021","unstructured":"Mechtler L, et al. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12: 788159.","journal-title":"Front Neurol"},{"key":"1077_CR56","unstructured":"Amgen USA. I., Aimovig [Package Insert]. 2020."},{"issue":"1","key":"1077_CR57","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, et al. Hypertension: a new safety risk for patients treated with erenumab. Headache. 2021;61(1):202\u20138.","journal-title":"Headache"},{"key":"1077_CR58","unstructured":"N\u00e4gel S, Cohen J, Kessler Y, Campos V, Ning X, Barash S, Nahas S.\u00a0Long-term fremanezumab treatment over 6 to 12 months shows no effect on blood pressure in migraine patients. in International Headache Society. 2021."},{"issue":"4","key":"1077_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen ID, et al. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021;4(4): e217934.","journal-title":"JAMA Netw Open"},{"key":"1077_CR60","doi-asserted-by":"crossref","unstructured":"Cetta I, et al.\u00a0Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report. J Neurol, 2022.","DOI":"10.1007\/s00415-022-11128-5"},{"issue":"10","key":"1077_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","volume":"28","author":"S Aradi","year":"2019","unstructured":"Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report. J Stroke Cerebrovasc Dis. 2019;28(10): 104286.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"1077_CR62","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/03331024211037277","volume":"42","author":"TD Rozen","year":"2022","unstructured":"Rozen TD, Bhatt AA. Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention. Cephalalgia. 2022;42(3):250\u20136.","journal-title":"Cephalalgia"},{"issue":"4","key":"1077_CR63","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88(4):771\u201384.","journal-title":"Ann Neurol"},{"issue":"3","key":"1077_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/CPJ.0000000000000651","volume":"9","author":"ED Goldstein","year":"2019","unstructured":"Goldstein ED, Badi MK, Meschia JF. Treating chronic migraine in CADASIL with calcitonin gene-related peptide receptor antagonism. Neurol Clin Pract. 2019;9(3):277\u20138.","journal-title":"Neurol Clin Pract"},{"issue":"4","key":"1077_CR65","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/head.14101","volume":"61","author":"S Naegel","year":"2021","unstructured":"Naegel S, et al. Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: a case report. Headache. 2021;61(4):694\u20136.","journal-title":"Headache"},{"issue":"1","key":"1077_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0333102420950484","volume":"41","author":"LL Lehman","year":"2021","unstructured":"Lehman LL, et al. Adverse effects of erenumab on cerebral proliferative angiopathy: a case report. Cephalalgia. 2021;41(1):122\u20136.","journal-title":"Cephalalgia"},{"issue":"14","key":"1077_CR67","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1177\/0333102420941814","volume":"40","author":"I de Boer","year":"2020","unstructured":"de Boer I, MaassenVanDenBrink A, Terwindt GM. The potential danger of blocking CGRP for treating migraine in CADASIL patients. Cephalalgia. 2020;40(14):1676\u20138.","journal-title":"Cephalalgia"},{"issue":"4","key":"1077_CR68","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/13892037113149990046","volume":"14","author":"B Holzmann","year":"2013","unstructured":"Holzmann B. Antiinflammatory activities of CGRP modulating innate immune responses in health and disease. Curr Protein Pept Sci. 2013;14(4):268\u201374.","journal-title":"Curr Protein Pept Sci"},{"issue":"1","key":"1077_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-021-01330-7","volume":"22","author":"JC Ray","year":"2021","unstructured":"Ray JC, et al. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22(1):121.","journal-title":"J Headache Pain"},{"issue":"23","key":"1077_CR70","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341.","journal-title":"N Engl J Med"},{"issue":"19","key":"1077_CR71","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"issue":"4","key":"1077_CR72","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642\u201352.","journal-title":"Headache"},{"issue":"4","key":"1077_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","volume":"61","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61(4):620\u20137.","journal-title":"Headache"},{"key":"1077_CR74","unstructured":"Shewale ARWP, Reed ML, Manthena S, Cadiou F, Burslem K, Lipton RB. AL060 Ubrogepant users' experience - patients on ubrogepant, characteristics and outcomes (UNIVERSE STUDY), in The International Headache Congress \u2013 IHS and EHF joint congress 2021. 2021.\u00a0J Headache Pain."},{"issue":"10200","key":"1077_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"issue":"2","key":"1077_CR76","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"key":"1077_CR77","doi-asserted-by":"crossref","unstructured":"Croop R, et al.\u00a0Long-term safety of rimegepant 75 mg for the acute treatment of migraine (Study 201), in American Headache Society 2020 Annual Meeting. 2020: Virtual.","DOI":"10.1212\/WNL.94.15_supplement.4829"},{"issue":"20","key":"1077_CR78","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121\u20135.","journal-title":"Neurology"},{"issue":"10268","key":"1077_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"1","key":"1077_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3\u201311.","journal-title":"Cephalalgia"},{"issue":"9","key":"1077_CR81","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19(9):727\u201337.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1077_CR82","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706.","journal-title":"N Engl J Med"},{"issue":"9","key":"1077_CR83","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcph.1610","volume":"60","author":"W Ankrom","year":"2020","unstructured":"Ankrom W, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol\/levonorgestrel oral contraceptive in healthy female participants. J Clin Pharmacol. 2020;60(9):1157\u201365.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1077_CR84","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, et al. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22(8):1857\u201363.","journal-title":"Pain Med"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-022-01077-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-022-01077-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-022-01077-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:43:44Z","timestamp":1727937824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-022-01077-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s11916-022-01077-z","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"24 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors report no other conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}